Skip to main content
. 2021 Nov 1;36(6):4349–4358. doi: 10.1007/s00464-021-08780-9

Table 1.

Patient characteristics of intracorporeal and extracorporeal groups

IA Group (RRCIA + LRCIA) N = 156 EA Group (RRCEA + LRCEA) N = 124 p value
Age (years) Mean ± SD 64.6 ± 11.1 67.2 ± 11.1 0.05
Sex, N (%) 0.06
Female 73 (46.8%) 72 (58.1%)
Male 83 (53.2%) 52 (41.9%)
Ethnicity, N (%) 0.003
Hispanic or Latino 19 (12.2%) 3 (2.4%)
Not Hispanic or Latino 137 (87.8%) 121 (97.6%)
Race, N (%) 0.05
Native American 2 (1.3%) 0
Asian 2 (1.3%) 4 (3.2%)
Black 11 (7.1%) 15 (12.1%)
White 140 (89.7%) 100 (80.6%)
Other 1 (0.6%) 5 (4.0%)
BMI Mean ± SD 30.4 ± 7.2 29.6 ± 5.6 0.30
ASA Classification, N (%) 0.33
ASA Class 1 7 (4.5%) 4 (3.2%)
ASA Class 2 58 (37.2%) 46 (37.1%)
ASA Class 3 85 (54.5%) 60 (48.4%)
ASA Class 4 6 (3.8%) 14 (11.3%)
 ≥ 1 comorbidities, N (%) 112 (71.8%) 102 (82.3%) 0.04
Hypertension 86 (55.1%) 79 (63.7%)
Myocardial infarction 10 (6.4%) 6 (4.8%)
Congestive heart failure 4 (2.6%) 9 (7.3%)
Coronary artery disease 20 (12.8%) 20 (16.1%)
Peripheral vascular disease 8 (5.1%) 7 (5.6%)
Cerebrovascular disease 10 (6.4%) 6 (4.8%)
COPD 8 (5.1%) 7 (5.6%)
Diabetes 29 (18.5%) 22 (17.7%)
Moderate/severe renal disease 4 (2.6%) 9 (7.3%)
Chronic steroid immunosuppressive use 2 (1.3%) 2 (1.6%)
Smoking status, N (%) 0.9373
Never smoked 100 (64.1%) 82 (66.1%)
Past smoker 43 (27.6%) 32 (25.8%)
Current smoker 13 (8.3%) 10 (8.1%)
Previous intestinal surgery, N (%) 54 (34.6%) 36 (29.0%) 0.32
Indication for surgery, N (%) 0.10
Benign neoplasm 76 (48.7%) 46 (37.4%)
Malignant neoplasm 79 (50.6%) 76 (61.8%)
Other 1 (0.6%) 1 (0.8%)
ERP, N (%) 100 (64.1%) 81 (65.3%) 0.761

RRCIA robotic-assisted right colectomy intracorporeal anastomosis, LRCIA laparoscopic right colectomy intracorporeal anastomosis, RRCEA robotic-assisted right colectomy extracorporeal anastomosis, LRCEA laparoscopic right colectomy extracorporeal anastomosis, BMI body mass index, ASA American Society of Anesthesiologists, SD standard deviation of the mean, COPD chronic obstructive pulmonary disease, ERP enhanced recovery pathway